pbpk modeling software gastroplus  (Simulations Plus Inc)

Journal: Pharmaceuticals

Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets

doi: 10.3390/ph18040562

Figure Lengend Snippet: Prediction results of candesartan American intravenous PBPK model.

Article Snippet: The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA).

Techniques:

Journal: Pharmaceuticals

Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets

doi: 10.3390/ph18040562

Figure Lengend Snippet: PBPK model predictions of 8 mg candesartan cilexetil tablets administered via preprandial oral route across ethnic populations. ( A ) Japanese and ( B ) Chinese.

Article Snippet: The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA).

Techniques:

Journal: Pharmaceuticals

Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets

doi: 10.3390/ph18040562

Figure Lengend Snippet: PBPK-model-predicted pharmacokinetic profiles of 8 mg candesartan cilexetil tablets following fasted oral administration in Chinese.

Article Snippet: The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA).

Techniques:

Journal: Pharmaceutics

Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

doi: 10.3390/pharmaceutics14010020

Figure Lengend Snippet: Validation results of the PBPK model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).

Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

Techniques: Biomarker Discovery

Journal: Pharmaceutics

Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

doi: 10.3390/pharmaceutics14010020

Figure Lengend Snippet: Prediction results of the oral LEV PBPK model in the Chinese pediatric population.

Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

Techniques:

Journal: Pharmaceutics

Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

doi: 10.3390/pharmaceutics14010020

Figure Lengend Snippet: Predicted results of the oral PBPK model in 4-year-old Chinese children. ( A ) 177.8 mg, q 12 h; ( B ) 300 mg + 200 mg, q 12 h.

Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

Techniques:

Journal: Pharmaceutics

Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

doi: 10.3390/pharmaceutics14010020

Figure Lengend Snippet: Prediction results of the 280 mg + 222.6 mg oral LEV-PBPK model in 6-year-old Chinese children. ( A ) Seven-day drug–time curve after normal administration; ( B ) 300 mg drug–time curve after remediation of a missed dose; ( C ) 275 mg drug–time curve after a missed dose; ( D ) 350 mg drug–time curve after remediation of a missed dose.

Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

Techniques: